Therapure BioPharma Inc

ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M

Retrieved on: 
Thursday, November 16, 2023
CNS, Ophthalmology, Attention deficit hyperactivity disorder, ADHD, Licensed production, IPO, Good agricultural practice, Partnership, Therapure BioPharma Inc, BioLite, Family, Drug development, MDD, Pharmaceutical industry, Polaris

The agreement has the potential of licensing income worth $467M and royalties up to $200M.

Key Points: 
  • The agreement has the potential of licensing income worth $467M and royalties up to $200M.
  • The Licensed Products for MDD and ADHD, owned by ABVC and its subsidiary BioLite, Inc., were valued at $667M by a third-party evaluation.
  • ABVC and AiBtl are determined to work to strengthen their new drug development and business collaboration.
  • "With ABVC as one of our major shareholders, holding 57% consolidated shares of AiBtl, we are proud to join the family of ABVC BioPharma.

Suzhou OSAI Biopharma Announces Positive Phase III Clinical Trial Results for Lactobacillus Crispatus Live Bacteria Capsule, Significantly Reducing Recurrence of Gynecological Infections

Retrieved on: 
Tuesday, December 12, 2023
Research, Infectious Diseases, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Science, Safety, Piper LBP, Incidence, Vaginitis, Gynaecology, Patient, Infection, Bacterial vaginosis, Medicine in China, MD, Phase, LBP, Obstetrics, Recurrence, BV, Therapure BioPharma Inc, Pharmaceutical industry

Suzhou OSAI Biopharma, Inc., a biopharmaceutical company focused on developing live biotherapeutic products (LBPs), today announced that its Phase III clinical trial of vaginal L. crispatus live bacteria capsule (Lc262-1) has successfully met its primary and secondary endpoints.

Key Points: 
  • Suzhou OSAI Biopharma, Inc., a biopharmaceutical company focused on developing live biotherapeutic products (LBPs), today announced that its Phase III clinical trial of vaginal L. crispatus live bacteria capsule (Lc262-1) has successfully met its primary and secondary endpoints.
  • The Phase III study was a multicenter, randomized, double-blind, placebo-controlled trial that enrolled 320 patients with bacterial vaginosis (BV).
  • After receiving seven days of oral metronidazole and vaginal LBP/placebo combination therapy, the cured patients were followed up for three months.
  • “This Phase III clinical trial is the first registrational Phase III clinical trial globally to evaluate the efficacy of L. crispatus in reducing BV recurrence under a rigorous clinical design.

Be Bio Announces New Preclinical Data Demonstrating its Novel Engineered B Cell Medicine (BCM), BE-101, Produces Active and Sustained Levels of Factor IX for the Treatment of Hemophilia B​

Retrieved on: 
Sunday, December 10, 2023
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Partial thromboplastin time, Safety, Haemophilia, Food, HDR, Engineering, Plasma, Hematology, Bio-MEMS, Mortality, CCR5, Mouse, Multimedia, BCMS, PCR, Defence Scientific Advisory Council, World government, WFH, FIX, Committee, Availability, Investigational New Drug, World Federation of Hemophilia, Factor IX, Human services, Cas9, Bleeding, Person, Pain, Drug discovery, American Society of Hematology, DdPCR, Coronavirus Scientific Advisory Board, Society, Cell, BCM, Real-time, AAV, ELISA, Immunoglobulin G, Therapure BioPharma Inc, Pharmaceutical industry, Vaccine

“We are excited by these findings as we advance this novel BCM into clinical development to address enduring unmet medical needs for people living with hemophilia B.

Key Points: 
  • “We are excited by these findings as we advance this novel BCM into clinical development to address enduring unmet medical needs for people living with hemophilia B.
  • Many people living with hemophilia B still experience bleeding episodes, irreversible joint damage and pain with current extended-release factor IX biologic therapy.
  • “Our goal is to create a new, potentially transformative treatment option that will provide people with hemophilia B the freedom to live a normal life, free of limitations from hemophilia B.
  • The data confirmed the expected biodistribution of FIX-expressing BCMs in bone marrow tissue, where they engraft stably over time.

Be Biopharma to Present at the 35th Annual Piper Sandler Healthcare Conference

Retrieved on: 
Wednesday, November 22, 2023
General Health, Health, Science, Other Science, Research, Conference, Engineering, Therapure BioPharma Inc, Pharmaceutical industry

Be Biopharma, Inc. (“Be Bio”), a company pioneering the discovery and development of Engineered B Cell Medicines (BeCMs), today announced that Chief Executive Officer Joanne Smith-Farrell, Ph.D., will present at the 35th Annual Piper Sandler Healthcare Conference being held at the Lotte New York Palace in New York, NY on Thursday, November 30, 2023.

Key Points: 
  • Be Biopharma, Inc. (“Be Bio”), a company pioneering the discovery and development of Engineered B Cell Medicines (BeCMs), today announced that Chief Executive Officer Joanne Smith-Farrell, Ph.D., will present at the 35th Annual Piper Sandler Healthcare Conference being held at the Lotte New York Palace in New York, NY on Thursday, November 30, 2023.

Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for Immunotherapy of Cancer

Retrieved on: 
Tuesday, November 7, 2023
Neoplasm, Survival, CAR, Combination, Glioma, Therapy, ASO, Regeneron Pharmaceuticals, Head, PD-1, The Co Founder, Merck, CNS, Microglia, Kidney, Bladder cancer, TLR9, OTCQB, CD8, Mouse, Environment, City, Immunotherapy, B cell, Disease, Survival rate, Brain, Society, GL261, Patient, Immunosuppression, Therapure BioPharma Inc, Pharmaceutical industry, Pembrolizumab, Cancer, Duet

NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (OTCQB: “SCPS”) and its majority-owned subsidiary, Duet BioTherapeutics Inc., presented compelling new data that DUET-102 in combination with PD-1 blockade demonstrates significant anti-tumor activity in models of malignant glioma.

Key Points: 
  • DUET-102 is a double-stranded antisense oligonucleotide (“ASO”) STAT3 inhibitor linked to a TLR9 immune activator being developed for the treatment of glioma.
  • Glioma is a common type of tumor originating in the glial cells of the brain.
  • DUET-102, as a monotherapy, inhibited tumor growth and extended survival of mice in U251, GL261, and QPP8 models of glioma.
  • There is an acute need for new treatment options for glioma, which have seen no significant advances in the past decade.

Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — to Present at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

Retrieved on: 
Thursday, November 2, 2023
Biotechnology, City, SITC, Immunotherapy, Society, Entrepreneurship, Therapure BioPharma Inc, OTCQB, Pharmaceutical industry, Tobacco, Cancer

NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (OTCQB: “SCPS”), a biotechnology company developing transformational therapeutics for serious diseases with significant unmet medical need, and its subsidiary, Duet BioTherapeutics Inc., which is developing novel immunotherapies to overcome treatment-resistant cancers, today announced that Marcin Kortylewski, Ph.D., Co-Founder and Senior Scientific Advisor of Duet and Professor of Immuno-Oncology at City of Hope, will be presenting at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC”).

Key Points: 
  • NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (OTCQB: “SCPS”), a biotechnology company developing transformational therapeutics for serious diseases with significant unmet medical need, and its subsidiary, Duet BioTherapeutics Inc., which is developing novel immunotherapies to overcome treatment-resistant cancers, today announced that Marcin Kortylewski, Ph.D., Co-Founder and Senior Scientific Advisor of Duet and Professor of Immuno-Oncology at City of Hope, will be presenting at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC”).
  • SITC is being held from November 3-5, 2023, in San Diego, California.
  • Details of the presentation are as follows:

FDA approves muscular dystrophy drug built on Children’s National research

Retrieved on: 
Friday, October 27, 2023
Prednisolone, Steroid, Faculty, FDA, Research, Non-Euclidean geometry, Food, European Commission, Facial muscles, Muscular dystrophy, Entrepreneurship, Vamorolone, Civil service commission, Growth, Duchenne muscular dystrophy, Department of Defence, DRS, Genetic distance, DMD, Invention, Patient, Bangladesh Technical Education Board, Therapure BioPharma Inc, Dietary supplement, Pharmaceutical industry

WASHINGTON, D.C., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Boys with Duchenne muscular dystrophy (DMD) have a clinically proven, new treatment option with the Food and Drug Administration’s approval Thursday of vamorolone, a steroidal-type, anti-inflammatory drug developed based on research performed at Children’s National Hospital.

Key Points: 
  • WASHINGTON, D.C., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Boys with Duchenne muscular dystrophy (DMD) have a clinically proven, new treatment option with the Food and Drug Administration’s approval Thursday of vamorolone, a steroidal-type, anti-inflammatory drug developed based on research performed at Children’s National Hospital.
  • Nearly two decades ago, ReveraGen leaders – President and CEO Eric Hoffman, Ph.D., and Vice President for Research Kanneboyina Nagaraju, D.V.M., Ph.D. – launched research efforts into the drug when they led the Center for Genetic Medicine Research at Children’s National.
  • DMD is the most common, severe and life-threatening form of muscular dystrophy.
  • “We cannot wait to see the tremendous effort behind vamorolone in the hands of patients and clinicians treating Duchenne muscular dystrophy,” Eskandanian said.

Be Biopharma to Present New Preclinical Study Demonstrating Its Precision-Engineered B Cell Medicine Produces Active and Sustained Levels of Factor IX

Retrieved on: 
Thursday, November 2, 2023
Biotechnology, Pharmaceutical, Health, Other Health, FIX, BCM, Factor IX, Therapure BioPharma Inc, Engineering, BCMS, Research, Blood, Society, Hematology, Pharmaceutical industry, ASH

The research will describe the development of an ex vivo precision-engineered B Cell Medicine (BCM) that produces active and sustained levels of factor IX (FIX).

Key Points: 
  • The research will describe the development of an ex vivo precision-engineered B Cell Medicine (BCM) that produces active and sustained levels of factor IX (FIX).
  • The abstract is now available online in a special issue of the ASH official journal, Blood .
  • “We look forward to presenting our research at the ASH annual meeting, the pre-eminent global congress for scientific exchange in hematology,” said Dr. Rick Morgan, Chief Scientific Officer, Be Bio.
  • “Our team of dedicated researchers is inspired by the potential of this bold new class of medicines.”
    Details of the oral presentation are as follows:

Be Biopharma Presents Preclinical Data Demonstrating Ex-Vivo Engineered B Cell Medicines Produce Highly Active and Sustained Levels of Antitumor Biologics

Retrieved on: 
Tuesday, October 31, 2023
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Plasma, Half-life, BCMS, Research institute, Seattle Children's, Therapure BioPharma Inc, Cell, Protein, B cell, Immunotherapy, Fragment crystallizable region, Society, Seattle, Patient, Engineering, ALL, Vaccine

“These findings underscore the clinical potential of BCMs as an emerging platform for sustained delivery of antitumor biologics.

Key Points: 
  • “These findings underscore the clinical potential of BCMs as an emerging platform for sustained delivery of antitumor biologics.
  • “Bispecific T cell engagers are highly effective in treating relapsed/refractory ALL; however, their short half-life requires continuous intravenous administration at high doses for four-week increments.
  • However, the short half-life of bispecific T cell engagers necessitates continuous intravenous administration at high doses for four weeks at a time.
  • To generate BCMs, B cells are engineered ex vivo to constitutively secrete transgenic biologics and then differentiated into plasma cells.

Be Biopharma Presents Data from Preclinical Studies Showing Engineered B Cells Produce Highly Active Therapeutic Proteins and Demonstrate Durable Engraftment Without Pre-Conditioning

Retrieved on: 
Wednesday, October 25, 2023
Oncology, Health, Stem Cells, General Health, Pharmaceutical, Biotechnology, Niemann–Pick disease, BCMS, Lysosomal storage disease, CRISPR, Therapure BioPharma Inc, CEST, Phenotype, Research, Protein, B cell, Mouse, Cell, Disease, LSD, Gene, ESGCT, FIX, BCM, European Society of Gene and Cell Therapy, Personal computer, Engineering, NHP, ASM, Vaccine

Today’s gene and cell therapies are potentially transformative medicines which can treat previously intractable diseases. However, there are barriers to the broad adoption of these therapies as current platforms struggle with drawbacks including inability to titrate dose and reliance on toxic preconditioning, among other challenges. Terminally differentiated human plasma cells (PCs) derived from genetically engineered B cells -- termed B Cell Medicines, or BCMs -- potentially offer natural longevity1, capacity for high levels of protein secretion (thousands of Ig molecules/cell/sec)2, ability to engraft without preconditioning, and the ability to redose.

Key Points: 
  • The data include durable in vivo production of the human clotting factor IX, prevention of tumor growth in a patient-derived xenograft model via a CD19xCD3 bispecific antibody, and engraftment without preconditioning in immunocompetent non-human primates (NHPs).
  • Also being presented are findings from a preclinical study showing BCMs are capable of producing highly active acid sphingomyelinase, the gene defective in Niemann-Pick disease, and correct the disease phenotype in knockout cells.
  • “These data highlight the therapeutic modularity and unique advantages of our BCM platform.”
    Today’s gene and cell therapies are potentially transformative medicines which can treat previously intractable diseases.
  • A BCM prototype engineered to express firefly luciferase with a phenotype of >90% CD27+CD38+ was injected via IV into immunodeficient mice, demonstrating rapid bone-marrow-homing and durable engraftment (>100 days).